Welcome to our dedicated page for XOMA Royalty Corporation SEC filings (Ticker: XOMAO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The XOMA Royalty Corporation Depositary Shares Rep Series B 8.375% Cumulative (XOMAO) SEC filings page on Stock Titan is intended to organize regulatory documents related to XOMA Royalty’s preferred stock and broader capital structure. While no specific SEC filings are listed in the provided data, XOMA Royalty’s press releases describe a business model and transaction activity that are typically reflected in formal filings such as annual reports, quarterly reports, and registration statements.
XOMA Royalty characterizes itself as a biotechnology royalty aggregator that acquires potential future economics associated with pre-commercial and commercial therapeutic candidates licensed to pharmaceutical or biotechnology companies. When it acquires these future economic rights, the seller receives non-dilutive, non-recourse funding. The company also explains that its portfolio consists of milestone and royalty rights associated with baskets of drug products in development, and that its assets are milestone and royalty rights tied to individual drug products.
For a security like XOMAO, which represents depositary shares of the 8.375% Series B Cumulative Perpetual Preferred Stock, SEC filings are the primary source for detailed terms of the preferred stock, including dividend provisions, ranking, and any redemption or liquidation preferences. In addition, XOMA Royalty’s acquisitions of companies such as HilleVax, LAVA Therapeutics, and Mural Oncology, along with royalty sharing transactions like the amended Takeda collaboration, are the types of material events that are generally described in current reports and periodic filings.
On Stock Titan, the XOMAO filings page can be used alongside XOMA Royalty’s public press releases to understand how the company reports its royalty and milestone portfolio, commercial assets such as VABYSMO, OJEMDA, MIPLYFFA, XACIATO vaginal gel 2%, IXINITY, and DSUVIA, and the impact of corporate transactions on its financial position. AI-powered summaries can help explain lengthy filings by highlighting sections that relate to preferred stock terms, royalty and milestone accounting, and the structure of acquisitions and royalty-sharing agreements.
Investors reviewing XOMAO may look to SEC documents for details on cumulative preferred dividend obligations, the relationship between the preferred stock and common equity, and disclosures about the risks and potential variability of royalty and milestone income. Combined with the company’s own explanatory notes on how it defines “portfolio” and “assets,” these filings provide a regulatory view of XOMA Royalty’s royalty aggregation strategy and the securities it has issued, including the Series B preferred stock represented by XOMAO.
XOMA ROYALTY CORPORATION ownership update: FMR LLC reports beneficial ownership of 1,268,506.14 shares of common stock, representing 10.2% of the class as of 02/27/2026. The filing also notes that Fidelity Contrafund held 773,332 shares, or 6.2%, as of the same date.
The schedule is an amendment (No. 5) and identifies filings and powers of attorney authorizing the submission; Exhibit 99 and related exhibits are referenced for subsidiary and agreement details.
XOMA Royalty Corporation furnished an updated corporate presentation outlining its royalty aggregation business model, portfolio, and preliminary 2025 financial data. The company focuses on acquiring early- to mid‑stage biotech royalty and milestone rights and highlights a diversified portfolio exceeding 100 assets, with more than $140M in milestones received since 2017 and over $2B in potential future milestones.
The presentation’s preliminary 2025 update shows $49–50M in cash received from royalties and milestones and about $133M of cash, cash equivalents and restricted cash as of December 31, 2025. XOMA repurchased and retired 648,048 common shares during 2025 for $16M, with 11,888,489 common shares outstanding as of February 27, 2026. General and administrative expenses for 2025 include roughly $1M tied to ongoing litigation with Janssen Biotech regarding use of XOMA intellectual property, and the company notes that the outcome and any potential recovery are uncertain.
Morgan Stanley and Morgan Stanley Investment Management Inc. filed an amended Schedule 13G reporting significant ownership in XOMA Royalty Corp common stock. They report beneficial ownership of 1,702,545 shares, representing 13.7% of the class, with voting and dispositive power shared through affiliated entities.
The filers state the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of XOMA Royalty Corp.
XOMA Royalty Corporation filed an amended report to give more detail on the legacy assets it acquired with LAVA Therapeutics. These include EGFRd2 (PF-8046052), outlicensed to Pfizer for cancers, and JNJ-89853413, outlicensed to Janssen Biotech for acute myeloid leukemia, both in early clinical trials with Pfizer and Janssen responsible for development and commercialization.
XOMA also acquired LAVA-1266 but does not plan further development and is seeking a sale or other disposition. Former LAVA shareholders received contingent value rights (CVRs) tied to any future monetization of these assets, with 75% of net proceeds payable through the CVRs. XOMA and LAVA previously estimated the CVR value at $0.00 because of the high uncertainty around early-stage oncology programs and limited prospects for LAVA-1266.